読み込み中
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
通常取引
$220.05
−$2.405 · -1.08%
日中の時刻はETです。市場データは遅延する場合があります。
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
日中レンジ
現在 $220.05
52週レンジ
現在 $220.05
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
54
適正価値
センチメント
57
まちまち
リスク
17
低リスク
モメンタム
66
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
日中レンジ
現在 $220.05
52週レンジ
現在 $220.05
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 42.68億 USD | 40.69億 USD | 38.34億 USD | 36.59億 USD | 30.94億 USD |
| 売上原価 | 5.03億 USD | 4.46億 USD | 4.36億 USD | 5.41億 USD | 4.41億 USD |
| 粗利益 | 37.64億 USD | 36.23億 USD | 33.99億 USD | 31.19億 USD | 26.53億 USD |
| 研究開発 | 7.83億 USD | 8.84億 USD | 8.5億 USD | 5.9億 USD | 5.06億 USD |
| 販売・一般管理 | 18.09億 USD | 13.85億 USD | 13.43億 USD | 14.17億 USD | 14.52億 USD |
| 営業費用 | 35.4億 USD | 29.07億 USD | 28.2億 USD | 31.84億 USD | 24.83億 USD |
| 支払利息 | 1.95億 USD | 2.38億 USD | 2.89億 USD | 2.88億 USD | 2.79億 USD |
| 減価償却費と償却費 | 6.96億 USD | 6.6億 USD | 6.39億 USD | 6.29億 USD | 5.52億 USD |
| 営業利益 | 2.24億 USD | 7.17億 USD | 5.79億 USD | −6552.8万 USD | 1.7億 USD |
| 純利益 | −3.56億 USD | 5.6億 USD | 4.15億 USD | −2.24億 USD | −3.29億 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$292.8
上昇余地（33.06%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI4.74億0.02%2.3兆 USD0.03%$382.02+0.65%
Vanguard Morningstar Small-Cap ETFVB3.44億0.18%1853億 USD0.03%$289.86+0.78%
Vanguard Morningstar Small-Cap Value ETFVBR2.18億0.32%682億 USD0.05%$234.76+0.36%
Vanguard Extended Market ETFVXF1.83億0.19%954億 USD0.05%$235.23+0.90%
Invesco S&P MidCap Momentum ETFXMMO1.56億2.21%70.83億 USD0.34%$149.16+1.21%
VictoryShares Free Cash Flow ETFVFLO1.47億1.29%111.86億 USD0.44%$53.005+0.20%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY1.07億0.42%255.28億 USD0.23%$670.95+0.70%
Dimensional - US Targeted Value ETFDFAT7851.17万0.26%302.58億 USD0.33%$67.495-0.10%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFInvesco S&P MidCap Momentum ETFXMMOVictoryShares Free Cash Flow ETFVFLOState Street SPDR S&P MIDCAP 400 ETF TrustMDYDimensional - US Targeted Value ETFDFATAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
